	US 11,702,704 B2
	Detecting ovarian cancer
William R. Taylor, Lake City, MN (US); John B. Kisiel, Rochester, MN (US); Douglas W. Mahoney, Elgin, MN (US); David A. Ahlquist, Rochester, MN (US); Hatim T. Allawi, Middleton, WI (US); and Michael W. Kaiser, Stoughton, WI (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US); and Exact Sciences Corporation, Madison, WI (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US); and Exact Sciences Corporation, Madison, WI (US)
Filed on Oct. 30, 2020, as Appl. No. 17/85,542.
Claims priority of provisional application 63/065,081, filed on Aug. 13, 2020.
Claims priority of provisional application 62/928,888, filed on Oct. 31, 2019.
Prior Publication US 2021/0130907 A1, May 6, 2021
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6869 (2018.01); C12N 15/117 (2010.01); G01N 33/50 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12N 15/117 (2013.01); C12Q 1/6869 (2013.01); G01N 33/50 (2013.01); C12Q 2521/301 (2013.01); C12Q 2523/125 (2013.01)]

17 Claims

1. A method, comprising:

treating genomic DNA from a biological sample from a human individual having or suspected of having an ovarian cancer with a reagent that modifies DNA in a methylation-specific manner;

amplifying the treated genomic DNA using a set of primers for at least one of CAPN2 and/or SIM2; and

determining a methylation level of at least one differentially methylated region (DMR) in CAPN2 and/or SIM2 using polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation, or target capture.